ArticleEndocrine2025
Evaluation of the predictive role of thyroglobulin antibodies combined with thyroid peroxidase antibodies on adverse pregnancy outcomes during early pregnancy.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe objective of this study was to explore whether combined assessment of TgAb and TPOAb perform a higher predictive value to adverse pregnancy outcomes than isolated TPOAb during early pregnancy.
methodsThis was a retrospective study of 4678 pregnant women receiving prenatal care at Peking University First Hospital from October 2017 to August 2018. Demographic and clinical data, including thyroid hormone levels, were retrieved from electronic medical records. The general information and incidence of adverse pregnancy outcomes were compared between different subgroups of thyroid function and antibody status.
resultsIn total, 2673 women were enrolled. 6.70% (179/2673) and 8.27% (221/2673) of the pregnant women were TPOAb positive and TgAb positive, respectively. The median thyroid-stimulating hormone (TSH) level was higher in the TPOAb or TgAb positive group than in the antibody-negative group [1.40 (0.96, 2.01) vs. 1.34 (0.86, 1.92), P = 0.045]. The prevalence of maternal composite outcomes (66.08% vs. 58.90%, p = 0.09) and fetal loss (10.49% vs. 5.78%, P = 0.02) was greater among women with 2.5 < TSH ≤ 4.08 mIU/L than among those with 0.23 < TSH ≤ 2.5 mIU/L. When the TSH concentration ranged from 0.23 to 2.5 mIU/L, the prevalence of fetal loss was greater in the TPOAb or TgAb positive group than in the antibody-negative group (8.33% vs. 5.43%, P = 0.04). Compared with TPOAb measruement alone, the predictive value of the TPOAb and TgAb combined assessment for maternal (AUC values: 0.509, 95% CI = 0.485 ~ 0.532) and fetal (AUC values: 0.512, 95% CI = 0.458 ~ 0.565) adverse outcomes was not higher.
conclusionUnder current treatment recommendations, the combined assessment of TPOAb and TgAb during pregnancy has limited predictive value for maternal-fetal adverse outcomes among euthyroid women compared with isolated TPOAb.
Indexed as
Identifiers
40736622What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.